Subscribe
istock-168586352_ll28
ll28 / iStockphoto.com
13 December 2018Biotechnology

FDA releases plan to boost biosimilars development

The US Food and Drug Administration (FDA) has announced new measures to advance the development of biosimilar medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Americas
FDA announces new measures to boost gene therapy innovation
16 January 2019   The US Food and Drug Administration has announced new policies to advance the development of safe and effective cell and gene therapies.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Americas
FDA announces new measures to boost gene therapy innovation
16 January 2019   The US Food and Drug Administration has announced new policies to advance the development of safe and effective cell and gene therapies.

More on this story

Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Americas
FDA announces new measures to boost gene therapy innovation
16 January 2019   The US Food and Drug Administration has announced new policies to advance the development of safe and effective cell and gene therapies.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB